Clinical Trials
Areas of focus
See the clinical trials for hereditary angioedema (HAE) and Netherton syndrome (NS) which use BioCryst medicines.
Clinical trials
Hereditary Angioedema
APeX-P (Active, Not Recruiting)
NCT05453968: This Phase 3 study is evaluating the pharmacokinetics and safety of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to <12 years old for prophylactic treatment to prevent attacks of HAE.
APeX-A (Active, Not Recruiting)
NCT04933721: This Phase 3b open-label study is providing access to berotralstat for patients with HAE who were previously enrolled in berotralstat studies.
Netherton Syndrome
Phase 1 study evaluating BCX17725 (Active, Recruiting)
NCT06539507: This is a first-in-human, Phase 1, three-part study that includes the evaluation of safety, tolerability, pharmacokinetics, and immunogenicity of BCX17725.
Expanding patient access to our medicines
We are a biotech company that is committed to identifying, developing, and delivering first-in-class or best-in-class small-molecule and protein therapeutics for patients living with HAE and other rare diseases.
A growing pipeline of small-molecule and protein therapeutics
BioCryst development programs represent the potential to improve the well-being of people whose lives are currently limited by HAE and other rare diseases. We discover novel, small-molecule and protein therapeutics that treat diseases in which significant unmet medical needs exist.